
Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Global Forecast 2024-2030
Description
Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Global Forecast 2024-2030
The Conjugate Vaccine Market size was estimated at USD 39.67 billion in 2023 and expected to reach USD 43.92 billion in 2024, at a CAGR 10.81% to reach USD 81.42 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Conjugate Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Conjugate Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..
Market Segmentation & Coverage
This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Monovalent
Multivalent
Indication
Diphtheria & Pertussis
Influenza
Meningococcal
Pneumococcal
Pathogen Type
Bacterial Conjugate Vaccine
Combination Conjugate Vaccine
Viral Conjugate Vaccine
End-User
Adults
Children
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Conjugate Vaccine Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Conjugate Vaccine Market?
3. What are the technology trends and regulatory frameworks in the Conjugate Vaccine Market?
4. What is the market share of the leading vendors in the Conjugate Vaccine Market?
5. Which modes and strategic moves are suitable for entering the Conjugate Vaccine Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Conjugate Vaccine Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
- 5.1.1.2. Rising adoption of cancer therapeutic vaccines
- 5.1.1.3. Rising number programs to promote vaccination by WHO
- 5.1.2. Restraints
- 5.1.2.1. Low accessibility to vaccines in remote areas
- 5.1.3. Opportunities
- 5.1.3.1. Government initiatives spreading awareness about infectious diseases
- 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
- 5.1.4. Challenges
- 5.1.4.1. Complexity of production procedure of conjugate vaccine
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Conjugate Vaccine Market, by Type
- 6.1. Introduction
- 6.2. Monovalent
- 6.3. Multivalent
- 7. Conjugate Vaccine Market, by Indication
- 7.1. Introduction
- 7.2. Diphtheria & Pertussis
- 7.3. Influenza
- 7.4. Meningococcal
- 7.5. Pneumococcal
- 8. Conjugate Vaccine Market, by Pathogen Type
- 8.1. Introduction
- 8.2. Bacterial Conjugate Vaccine
- 8.3. Combination Conjugate Vaccine
- 8.4. Viral Conjugate Vaccine
- 9. Conjugate Vaccine Market, by End-User
- 9.1. Introduction
- 9.2. Adults
- 9.3. Children
- 10. Americas Conjugate Vaccine Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Conjugate Vaccine Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Conjugate Vaccine Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Bavarian Nordic
- 14.1.2. Bharat Biotech Ltd.
- 14.1.3. Bio-Med Limited
- 14.1.4. Biological E. Limited
- 14.1.5. Biological E. Ltd
- 14.1.6. CSL Limited
- 14.1.7. GlaxoSmithKline, plc.
- 14.1.8. Merck and Company
- 14.1.9. Novartis AG
- 14.1.10. Nuron Biotech Inc.
- 14.1.11. Pfizer, Inc.
- 14.1.12. Sanofi Pasteur U.S., LLC
- 14.1.13. Serum Institute of India Pvt. Ltd.
- 14.1.14. Taj Pharmaceuticals Limited
- 14.1.15. Vaxcyte, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
- FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2023 VS 2030
- FIGURE 3. CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. CONJUGATE VACCINE MARKET DYNAMICS
- FIGURE 7. CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2030 (%)
- FIGURE 12. CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 14. CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.